Jeffrey T. Walsh
Independent DirectorMr. Jeffrey T. Walsh, also known as Jeff, is Chief Executive Officer & Director of nChroma Bio, bringing over years of leadership experience in both public and private life sciences companies. He joined nChroma in December 2024, following his tenure as CEO of Nvelop Therapeutics, where he led through its merger with Chroma Medicine. Prior to Nvelop, Jeff was a Venture Partner at Third Rock Ventures, focusing on next-generation gene and cell therapy opportunities. From 2011 to 2020, he held key executive roles at bluebird bio, including Chief Financial and Strategy Officer and Chief Operating Officer. In his career, he served as Chief Business and Financial Officer at Taligen Therapeutics, where he played a pivotal role in the company’s acquisition by Alexion Pharmaceuticals. He also held business development and finance positions at Pathogenesis (acquired by Chiron), EXACT Sciences, Allscripts and SmithKline Beecham. Mr. Walsh has B.A. in Sociology, Economics from Yale University. Mr. Walsh has M.B.A. from Kellogg School of Management.
Positions
- Company NameTenaya Therapeutics, Inc.Stock CodeTNYAPositionIndependent DirectorColleagues
- FAFaraz AliPresident, CEO & Director
- DSDeepak SrivastavaScientific Founder, Chairman of Scientific Advisory Board & Director
- WGWhittemore G. TingleyChief Medical Officer
- ENEric N. OlsonScientific Founder & Member of Scientific Advisory Board
- BRBruce R. ConklinScientific Founder
- JHJune H. LeeIndependent Director
